Calidi Biotherapeutics, Inc. (CLDI) is a publicly traded Healthcare sector company. As of May 21, 2026, CLDI trades at $0.17 with a market cap of $2.79M and a P/E ratio of -0.03. CLDI moved -8.04% today. Year to date, CLDI is -85.53%; over the trailing twelve months it is -96.84%. Its 52-week range spans $0.16 to $46.68. Rallies surfaces CLDI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in CLDI news today?
Calidi Biotherapeutics Narrows Q1 Net Loss to $4.4M, Raises Cash to $6.6M and Secures AI Partnership: Calidi Biotherapeutics narrowed its Q1 2026 net loss to $4.4M from $5.0M year-earlier, cut G&A expenses by $1.0M to $1.6M, and increased cash reserves to $6.6M. The company disclosed new CLD-401 and CLD-501 activation data at cancer research conferences and forged a TransferAI collaboration to streamline its CLD-401 IND filing.
Schoeneck James A bought 75.00K (~$150.00K) on Aug 21, 2025.
Poma Eric E bought 25.00K (~$50.00K) on Aug 21, 2025.
CLDI Analyst Consensus
CLDI analyst coverage data. Average price target: $0.00.
Common questions about CLDI
What changed in CLDI news today?
Calidi Biotherapeutics Narrows Q1 Net Loss to $4.4M, Raises Cash to $6.6M and Secures AI Partnership: Calidi Biotherapeutics narrowed its Q1 2026 net loss to $4.4M from $5.0M year-earlier, cut G&A expenses by $1.0M to $1.6M, and increased cash reserves to $6.6M. The company disclosed new CLD-401 and CLD-501 activation data at cancer research conferences and forged a TransferAI collaboration to streamline its CLD-401 IND filing.
Does Rallies summarize CLDI news?
Yes. Rallies summarizes CLDI news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is CLDI research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CLDI. It does not provide personalized investment advice.
